Roivant Sciences ROIV
NASDAQ ROIV
$35.72 +0.22 (+0.62%)
At close: Oct 2, 2026 · 4:00 PM EDT

Roivant Sciences (ROIV) Gains from Sales and Divestitures (2023 - 2024)

Updated

Roivant Sciences (ROIV) recorded Gains from Sales and Divestitures of $110.39 million in fiscal Q1 2025 (quarter ended Jun 30, 2024).

Analysis

Roivant Sciences (ROIV) Gains from Sales and Divestitures (2023 - 2024) Analysis & Trends

For FY2024 (ended Mar 31, 2024), Roivant Sciences reported Gains from Sales and Divestitures of $5.35 billion.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Roivant Sciences 25.81 Bn 26.50 Bn 1.16 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 110.39 Mn
Dec 31, 2023 5.35 Bn
API Access

Roivant Sciences Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ROIV&period=max&api_key=YOUR_API_KEY